These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31011901)

  • 21. ASO Author Reflections: Radiopathomics Strategy of Combing Multi-scale Tumor Information on Pretreatment to Predict the Pathologic Response to Neoadjuvant Therapy.
    Tian J; Fan X; Xu R; Sun YS; Yang G
    Ann Surg Oncol; 2020 Oct; 27(11):4307-4308. PubMed ID: 32495287
    [No Abstract]   [Full Text] [Related]  

  • 22. ASO Author Reflections: Tailoring of Targeted Axillary Dissection-Intraoperative Nodal Evaluation Reduces Second Operations.
    Wu S; Liu G
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):634-635. PubMed ID: 30411270
    [No Abstract]   [Full Text] [Related]  

  • 23. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of pathologic complete response and the alteration of breast cancer immunohistochemical biomarkers after neoadjuvant chemotherapy.
    Shuai Y; Ma L
    Pathol Res Pract; 2019 Jan; 215(1):29-33. PubMed ID: 30501932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer.
    Pereira CBL; Leal MF; Abdelhay ESFW; Demachki S; Assumpção PP; de Souza MC; Moreira-Nunes CA; Tanaka AMDS; Smith MC; Burbano RR
    Clin Breast Cancer; 2017 Jun; 17(3):188-194. PubMed ID: 28089283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ASO Author Reflections: Multimodality Therapy for Patients with Pancreatic Cancer: Neoadjuvant Therapy for All?
    da Costa WL; Massarweh NN
    Ann Surg Oncol; 2021 Jun; 28(6):3196-3197. PubMed ID: 33221979
    [No Abstract]   [Full Text] [Related]  

  • 28. ASO Author Reflections: Mammographic Microcalcifications in Neoadjuvant Patients: Author Reflections.
    Azam R; Lim D; Curpen B; Mulligan AM; Hong NL
    Ann Surg Oncol; 2023 Jul; 30(7):4132-4133. PubMed ID: 37120486
    [No Abstract]   [Full Text] [Related]  

  • 29. ASO Author Reflections: Neoadjuvant Chemotherapy Switch: Optimizing Neoadjuvant Treatment Sequencing in Pancreas Cancer.
    Alva-Ruiz R; Truty MJ
    Ann Surg Oncol; 2022 Mar; 29(3):1592-1593. PubMed ID: 34705142
    [No Abstract]   [Full Text] [Related]  

  • 30. ASO Author Reflections: Entering the Era of Biomarker-Driven Management of the Axilla.
    DiNome ML; Marzese DM
    Ann Surg Oncol; 2022 Aug; 29(8):4725-4726. PubMed ID: 35415817
    [No Abstract]   [Full Text] [Related]  

  • 31. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.
    Tiezzi DG; Andrade JM; Ribeiro-Silva A; Zola FE; Marana HR; Tiezzi MG
    BMC Cancer; 2007 Feb; 7():36. PubMed ID: 17324279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ASO Author Reflections: Combining Intensive Neoadjuvant Therapy with Minimally Invasive Surgery: A Promising Future Strategy for Rectal Cancer with High-Risk Features.
    Konishi T; Shinozaki E
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):753-754. PubMed ID: 31571051
    [No Abstract]   [Full Text] [Related]  

  • 33. ASO Author Reflections: Is Neoadjuvant Chemotherapy Associated with Acceptable Short-Term Outcomes for Pancreatic Cancer?
    Kamarajah SK; Dahdaleh F
    Ann Surg Oncol; 2021 Apr; 28(4):1906-1907. PubMed ID: 33389290
    [No Abstract]   [Full Text] [Related]  

  • 34. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
    Wang-Lopez Q; Chalabi N; Abrial C; Radosevic-Robin N; Durando X; Mouret-Reynier MA; Benmammar KE; Kullab S; Bahadoor M; Chollet P; Penault-Llorca F; Nabholtz JM
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):88-104. PubMed ID: 25900915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ASO Author Reflections: Breast Cancer Local Recurrence Versus New Primary-Clinical Predictors and Prognostic Implications.
    Laird J; Braunstein LZ
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):648-649. PubMed ID: 30306376
    [No Abstract]   [Full Text] [Related]  

  • 36. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
    Dong T; Kang X; Liu Z; Zhao S; Ma W; Xuan Q; Liu H; Wang Z; Zhang Q
    Tumour Biol; 2016 Jun; 37(6):8159-68. PubMed ID: 26715276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients.
    Mark KMK; Varn FS; Ung MH; Qian F; Cheng C
    BMC Cancer; 2017 May; 17(1):306. PubMed ID: 28464832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized Feasibility Study of
    Chae SY; Kim SB; Ahn SH; Kim HO; Yoon DH; Ahn JH; Jung KH; Han S; Oh SJ; Lee SJ; Kim HJ; Son BH; Gong G; Lee HS; Moon DH
    J Nucl Med; 2017 Apr; 58(4):563-568. PubMed ID: 27688475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Prognostic Value of a Pathologic Complete Response After Neoadjuvant Therapy for Digestive Cancer: Systematic Review and Meta-Analysis of 21 Studies.
    Wan T; Zhang XF; Liang C; Liao CW; Li JY; Zhou YM
    Ann Surg Oncol; 2019 May; 26(5):1412-1420. PubMed ID: 30805807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.